fax: 919-544-4410
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus†
Article first published online: 22 DEC 2010
DOI: 10.1002/hep.24078
Copyright © 2010 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Snow-Lampart, A., Chappell, B., Curtis, M., Zhu, Y., Myrick, F., Schawalder, J., Kitrinos, K., Svarovskaia, E. S., Miller, M. D., Sorbel, J., Heathcote, J., Marcellin, P. and Borroto-Esoda, K. (2011), No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology, 53: 763–773. doi: 10.1002/hep.24078
- †
Potential conflict of interest: The studies were sponsored by Gilead Sciences, and all non-Gilead employees received payment for their participation in the trials.Dr. Marcellin received grants and is on the speakers' bureau of Roche, Schering-Plough, Gilead, Bristol0Myers Squibb, Vertex, Novartis, Pharmasset, Tibotec, MSO, Baehringer, Biolex, Intermune, and Zynogenetics.Dr. Sorbel owns stock in and received grants from Triangle Biostatistics.Dr. Heathcote consults for, advises, is on the speakers' bureau of, and received grants from Gilead. She consults for, is on the speakers' bureau of, and received grants from Axcan Pharma, Hoffman-LaRoche, Merck, and Tibotec. She also received grants from Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Intercept Pharma, and Vertex.
- ‡
fax: 919-544-4410
Publication History
- Issue published online: 2 MAR 2011
- Article first published online: 22 DEC 2010
- Accepted manuscript online: 18 NOV 2010 11:21AM EST
- Manuscript Accepted: 8 NOV 2010
- Manuscript Received: 21 JUL 2010
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, A Cutting-Edge View on the Current State of Antiviral Drug Development, Medicinal Research Reviews, 2013, 33, S1Direct Link:
- 2, , , , Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential, Journal of Gastroenterology, 2013,
- 3, , , Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy, Virus Genes, 2013,
- 4, , , , , , , , , , , , Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load, Hepatology, 2013, 57, 5Direct Link:
- 5, , , , , , , , , , , , GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees, Gastroenterology, 2013,
- 6, , Hepatitis B viral factors and treatment responses in chronic hepatitis B, Journal of the Formosan Medical Association, 2013,
- You have free access to this content7, , Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?, Clinical Liver Disease, 2013, 2, 1Direct Link:
- 8, , , , , , , , , Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen, Journal of Viral Hepatitis, 2013, 20, 2Direct Link:
- You have free access to this content9, , Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance, Liver International, 2013, 33,Direct Link:
- 10, , , , Resistance is no Longer a Problem with Entecavir and Tenofovir, Current Hepatitis Reports, 2013,
- You have free access to this content11, Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues, Liver International, 2013, 33,Direct Link:
- 12, , , , , Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management, Expert Opinion on Biological Therapy, 2012, 12, 2, 193
- 13, , Authors' reply: Current strategies in the management of hepatitis B virus reactivation, Nature Reviews Clinical Oncology, 2012, 9, 6, 350
- 14, , , Chronic hepatitis B in children and adolescents, Journal of Hepatology, 2012, 57, 4, 885
- 15
- 16, Clinical trials and their translation in hepatology: Past, present, and future, Hepatology, 2012, 56, 2Direct Link:
- 17, , , Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs, Future Virology, 2012, 7, 2, 139
- 18, , , , Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada, Value in Health, 2012, 15, 6, 894
- 19, Drugs in Development for the Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 111
- 20, , , , , , , , , , , Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B, Gastroenterology, 2012, 143, 3, 619
- 21, , First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice, Journal of Viral Hepatitis, 2012, 19, 6Direct Link:
- 22KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109
- 23, , , , , , , , Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection, Journal of Clinical Virology, 2012, 53, 2, 130
- 24, , , , Prevention and management of drug resistant hepatitis B virus infections, Journal of Gastroenterology and Hepatology, 2012, 27, 9Direct Link:
- 25, , , , , , , , , , , , Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2012, 35, 9Direct Link:
- 26, , , , , , , , Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2012, 35, 11Direct Link:
- 27, , Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 55
- 28, , , , Selection of chronic hepatitis B therapy with high barrier to resistance, The Lancet Infectious Diseases, 2012, 12, 4, 341
- 29, , , , , , , , , , Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation, Liver International, 2012, 32, 7Direct Link:
- 30, , Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B, Expert Review of Gastroenterology & Hepatology, 2012, 6, 4, 413
- 31, Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?, Medicinal Research Reviews, 2012, 32, 4Direct Link:
- 32, , The Evolution of Drug Resistance Interpretation Algorithms: ANRS, REGA and Extension of Resistance Analysis to HIV-1 Group O and HIV-2, Intervirology, 2012, 55, 2, 128
- You have free access to this content33, , , , Treatment of human immunodeficiency virus and hepatitis B virus infections, Haemophilia, 2012, 18,Direct Link:
- 34, , , , Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety, Current Hepatitis Reports, 2011, 10, 4, 235
- 35, , , , , , , , , , , , , Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study, Antiviral Research, 2011, 92, 1, 90
- 36, Hepatitis: Treatment failure in chronic hepatitis B, Nature Reviews Gastroenterology & Hepatology, 2011, 8, 7, 366
- 37, , , Management of chronic hepatitis B, European Journal of Gastroenterology & Hepatology, 2011, 23, 8, 642
- 38, , , , , , , Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV–Coinfected Adults With Persistent HBV Viremia, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011, 58, 3, e96
- 39
- 40